0 423

Cited 6 times in

The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.

DC Field Value Language
dc.contributor.author박무석-
dc.contributor.author손주혁-
dc.contributor.author신상준-
dc.contributor.author장준-
dc.contributor.author김대준-
dc.contributor.author정경영-
dc.contributor.author김세규-
dc.contributor.author조병철-
dc.contributor.author김세현-
dc.contributor.author최혜진-
dc.contributor.author김주항-
dc.date.accessioned2015-05-19T17:41:45Z-
dc.date.available2015-05-19T17:41:45Z-
dc.date.issued2008-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/108639-
dc.description.abstractThe prognosis of patients with stage III non-small-cell lung cancer (NSCLC) who achieve a pathological complete response or downstaging following neoadjuvant therapies are better than the prognosis of patients with residual metastatic lymph nodes (LN). However, the prognostic significance of the number of residual metastatic LNs remains unclear. From January 2001 to January 2006, 42 consecutive patients with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 patients) were treated with neoadjuvant chemotherapy. Thirty-four (81.0%) of the 42 patients were pathologically staged by mediastinoscopy. Neoadjuvant chemotherapy consisted of 3 cycles of platinum-based doublet (21 patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). After neoadjuvant chemotherapy, a pathological complete response was achieved in one patient and downstaging was achieved in 24 patients. Pathological LN metastasis was absent in 9 patients (21.4%) and present in 33 patients (78.6%). With a median follow-up of 23 months, the 2-year disease-free survival (DFS) rate of patients without residual LN metastasis was statistically better than that of patients with residual LN metastasis (46% vs. 18% respectively, P=0.03). Among 33 patients with residual LN metastasis, age (P=0.01), pathological downstaging (P=0.098) and the number of residual metastatic LNs (median 14 months in 1-4 LN vs. median 5 months in LN > or =5; P=0.011) were significant predictors of DFS in univariate analysis. In multivariate analysis, the number of residual metastatic LNs was an independent predictor of DFS among patients with residual LN metastasis, irrespective of pathological downstaging. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy is an independent predictor of DFS in patients with stage III NSCLC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent393~400-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/blood-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology*-
dc.subject.MESHCisplatin/administration & dosage*-
dc.subject.MESHDocetaxel-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/blood-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHLung Neoplasms/pathology*-
dc.subject.MESHLymphatic Metastasis-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHPaclitaxel/administration & dosage*-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTaxoids/administration & dosage*-
dc.subject.MESHVinblastine/administration & dosage-
dc.subject.MESHVinblastine/analogs & derivatives*-
dc.subject.MESHVinorelbine-
dc.titleThe number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery (흉부외과학)-
dc.contributor.googleauthorSe Hyun Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorHye Jin Choi-
dc.contributor.googleauthorKyung Young Chung-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorMoo-Suk Park-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorSang-Joon Shin-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorJoo Hang Kim-
dc.identifier.doi10.1016/j.lungcan.2007.11.004-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01457-
dc.contributor.localIdA01995-
dc.contributor.localIdA02105-
dc.contributor.localIdA03472-
dc.contributor.localIdA00368-
dc.contributor.localIdA03571-
dc.contributor.localIdA00602-
dc.contributor.localIdA03822-
dc.contributor.localIdA00607-
dc.contributor.localIdA04219-
dc.contributor.localIdA00945-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid18155802-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500207006691-
dc.subject.keywordNeoadjuvant chemotherapy-
dc.subject.keywordLymph node-
dc.subject.keywordPrognostic-
dc.subject.keywordStage III-
dc.subject.keywordNSCLC-
dc.subject.keywordDownstaging-
dc.subject.keywordSurvival-
dc.contributor.alternativeNamePark, Moo Suk-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameChang, Joon-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.alternativeNameChung, Kyung Young-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameKim, Se Hyun-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.affiliatedAuthorPark, Moo Suk-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorChang, Joon-
dc.contributor.affiliatedAuthorKim, Dae Joon-
dc.contributor.affiliatedAuthorChung, Kyung Young-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorKim, Se Hyun-
dc.contributor.affiliatedAuthorChoi, Hye Jin-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.rights.accessRightsnot free-
dc.citation.volume60-
dc.citation.number3-
dc.citation.startPage393-
dc.citation.endPage400-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.60(3) : 393-400, 2008-
dc.identifier.rimsid37145-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.